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Abstract 
Introduction 
Conventional split skin grafts (SSG) require anaesthesia, specialist equipment and can have high 
donor site (DS) morbidity. The CelluTome epidermal-graft-harvesting-device is a novel alternative, 
providing pain-free epidermal skin grafts (ESG) in the outpatient setting with projected minimal DS 
trauma and improved patient satisfaction. This study aimed to compare ESG with SSG by evaluat-
ing patient related outcome measures (PROMs) and cost implications of both.  
Methods  
Twenty patients answered a graft satisfaction questionnaire which evaluated: donor/graft site no-
ticeability, aesthetic concerns, adverse problems and patient satisfaction. Cost/patient was calcu-
lated based on total operative expenses and five clinic followups. 
Results  
In 100% of ESG cases there were no DS noticeability or adverse problems compared to 25% in 
the SSG group. Complete satisfaction with DS appearance was observed in 100% of ESG cases 
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(50% SSG). Noticeability, adverse problems and overall satisfaction were significantly better in 
ESG (p<0.05). Graft site parameters were comparable with similar healing outcomes. 
The cost per patient for ESG was £431 and £1489 for SSG with an annual saving of £126960 
based on ten grafts/month. 
Conclusion 
For the right patient, CelluTome provides comparable wound healing with reduced DS morbidity 
and higher patient satisfaction. 
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Key Messages 
- Epidermal skin grafting with the CelluTome device may provide better donor site results 
and have improved patient satisfaction compared to conventional split skin grafting 
- The aim of the study was to evaluate patient recorded outcome measures and cost impli-
cations of epidermal and split skin grafts through the use of questionnaires 
- Epidermal graft donor sites had significantly better noticeability scores with significantly 
fewer adverse outcomes and better patient satisfaction. Graft site satisfaction and heal-
ing outcomes were similar in both groups. There was a saving of £1058 per patient when 
using epidermal grafting compared to split skin grafting. 
Reviewers: 
Pari Mohanna 
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Naveen Cavale 
Haroon Mann 
Text 
Introduction 
CelluTome (Acelity, USA) is a novel device which harvests the epidermal layer of the skin through 
suction blister formation providing autologous keratinocytes for grafting (1). It acts through a com-
bination of the application of heat (up to 40 degrees) and a negative pressure (400-500mmHg) to 
provide epidermal skin grafts (ESG) in an out-patient setting, which cause minimal or no pain with 
reduced donor site (DS) trauma and without the need for anaesthesia: leading to improved patient 
satisfaction compared with other skin grafting procedures. The device carries a one-off cost of ap-
proximately £7500. 
The technique of suction blistering of the epidermis was first described in 1964 by Kiistala and 
Mustakallio (2). Their technique proposed complete detachment of the epidermis from dermis at 
the dermo-epidermal junction with the application of negative pressure (150 – 200mmHg), with 
minimal intra-operative trauma.  However, it was not until 1971, that Falabella (3) first described 
the use of this technique to provide an ESG, showing that ESG was a valuable tool for providing 
coverage of granulating areas and repigmentation of achromic lesions.  Falabella’s work opened 
up the possibility of using this technique to cover various different types of granulating wounds and 
has, since then, been used widely by dermatologists in the treatment of Vitiligo.  Despite this, the 
use of ESG in the management of non-healing chronic wounds or acute wounds with poor tissue 
coverage, to-date has been minimally explored. 
 
Wound management costs the NHS an estimated £2.3 – 3.1 billion per annum (4). The majority of 
wounds are managed in the outpatient setting with protocols that vary according to geography, in-
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stitution and speciality: despite this, split skin grafts (SSG) remain the standard treatment for defini-
tive wound closure for wounds with granulating bed. Split skin grafts require a dedicated room or 
theatre with the correct equipment, anaesthesia (whether local, regional or general), a period of 
immobility for some patients, occasionally hospital admission and are associated with high DS 
morbidity, requiring attentive DS wound care and pain management. Cellutome provides similar 
wound cover with minimal or pain-free epidermal skin grafts in an outpatient setting, without the 
need for anaesthesia or additional instruments.  
 
Our study aims to evaluate the patient reported outcome and cost efficiency of using CelluTome to 
provide ESG in an outpatient setting against SSG. Evidence has shown that the systematic use of 
information from patient recorded outcome measures (PROMs) leads to overall better decision 
making between doctors and patients and results in patients being more satisfied with their treat-
ment [5]. By comparing PROMs and the cost of ESG versus SSG in an analogous cohort of pa-
tients, we aim to determine if CelluTome is a viable alternative to current wound management 
technique besides being cost effective for the NHS and patient.  
 
Methods 
Patient Reported Outcome Measures (PROMs) 
Twenty demographically matched patients (ten who had undergone SSG and ten who had under-
gone ESG with CelluTome) were selected for inclusion in the study (Table 1). All patients received 
grafting once wounds showed healthy granulation tissue with good vascularity. PROMs were as-
sessed using a validated patient skin graft satisfaction questionnaire (Appendix 1).  All patients 
received the questionnaire at least six weeks after their procedure. The questionnaire assessed 
patient views on donor and graft site, noticeability; problems; concerns about cosmetic appear-
ance; and, overall outcome. The results were found to be non-normally distributed using Shapiro-
Wilk normality test and were analysed using the Mann-Whitney U test. 
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Patients also underwent weekly wound assessment in dressings clinic to monitor progress of heal-
ing. 
Cost Analysis 
A calculation was made for expenditure and income for inpatient split skin grafting, a CelluTome 
procedure and conservative dressing management. The cost of each patient event was calculated 
using the corresponding OPSC codes and overall cost of each treatment event was calculated as 
an average of the patients included in this study taking into account co-morbidities. 
For both the SSG and CelluTome procedures costing included one initial and four follow-up dress-
ing clinic appointments, the average standard practice in our department. For conservative dress-
ing management, costing included one initial and fourteen follow-up dressing clinic appointments. 
An annual cost was also calculated based on an estimate of ten patients per month, which is the 
expected case volume once the service is fully operational. 
 
Results 
Patient Recorded Outcome Measures 
Donor site: 
There was no DS noticeability, adverse problems or concerns in 100% of patients undergoing 
ESG. All patients were either very (80%) or somewhat (20%) satisfied with their donor site out-
come. All donor sites healed fully with an average healing time of 5 days. 
 
In comparison, only two patients in the SSG group stated that they did not find their donor site no-
ticeable with six patients finding it either somewhat or very noticeable. Six of the SSG patients 
found their donor site to be problematic to some degree. Four patients were unsatisfied to some 
degree with the overall outcome. However, only two patients were concerned about their donor site 
appearance. All donor sites healed fully. 
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DS noticeability, adverse problems and overall satisfaction were statistically significantly better in 
ESG (p<0.05). ). Table 2 shows a summary of all the results regarding the donor site in the ESG 
and SSG groups respectively.  
 
 
Graft recipient site:  
Overall, 80% of ESG patients were completely satisfied with the appearance of their graft site.  On-
ly 30% of patients found their graft site very noticeable, whilst 10% found it not noticeable at all.  
40% of patients had no concerns or adverse problems with their graft site.  Those that complained 
of it being problematic were referring to the length of time it took for the graft to heal, but none 
complained about pain or infection.  
 
Eight ESG patients had evidence of healing at the graft site, with two having a 50% reduction in 
wound size and six having a 100% reduction. Average healing time for 100% reduction was six 
weeks. Two patients had failed grafts. 
 
The graft site in SSG was noticeable to some degree in all patients, with 70% of patients finding it 
very or somewhat noticeable.  Despite this the majority of patients (70%) were not concerned at all 
about their graft site appearance, with only two patients suffering adverse problems. Overall satis-
faction rates showed 100% of people were satisfied to some degree.  The results of the statistical 
analysis for the CelluTome and SSG graft sites are summarised in Table 3.  There was no statisti-
cally significant difference in the outcomes of the two groups.  
 
Four SSG patients had 100% reduction in wound size, with the other six having at least 50% re-
duction. Average healing time for 100% reduction was 9 weeks. There were no graft failures. One 
patient suffered a graft site infection requiring a course of antibiotics. Two patients expressed dis-
satisfaction at long healing times. A comparison of ESG and SSG graft site healing is shown in 
Table 4. 
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Cost Analysis 
The average individual cost and income per patient event are summarised in Table 5. The overall 
loss/profit per treatment option (including dressing clinic followup) for individual patients and annu-
ally are summarised in Table 6. The comparisons between overall individual cost per treatment 
option is illustrated in Figure 1. 
 
Discussion 
Management of acute and chronic wounds costs the NHS billions of pounds per annum and has 
been identified by the WHO as a significant health problem (6). Current management options in-
clude split skin grafting or conservative management. However, SSG often requires anaesthesia in 
a setting with access to the correct equipment, and can cause significant donor site morbidity and 
discomfort for the patient. Conservative dressing management is often an extremely long process 
requiring many attendances by nurses (either in the community or in a hospital dressing clinic) with 
varying outcomes and occasional progression to theatre for a SSG or commencement of negative 
pressure wound therapy. 
Epidermal graft harvesting has previously been shown to be effective in the management of lower 
limb wounds (7-10). Recent case series have also shown that the CelluTome epidermal graft har-
vesting device is effective in managing a variety of acute and chronic wounds in a wide range of 
patients, offering a viable alternative to SSG (11-13). 
Our study is the first to evaluate patient related outcome measures in patients treated with the Cel-
luTome device. Currently there is a growing need for transparency in results and procedural out-
comes from both operator and patient’s perspective.  Chronic non healing wounds often cause 
stress and morbidity to patients.  Treatment options that do not involve anaesthesia, donor site 
morbidity and an admission to hospital (whether as a day case or longer stay) should be widely 
 8 
available. PROMs have been used to monitor outcomes for certain procedures in the surgical 
community for several years now.  They have been widely shown to improve public transparency, 
aid surgeons to improve their practice, to offer patients informed choices about their care, whilst 
aiding health service commissioners to make sensible funding decisions (14). Subjective rating 
scale questionnaires such as the one used in this study are validated tools for assessment of psy-
chological impact of skin grafting and provide a review of a patient’s opinion on a specific treatment 
(15). 
We found that 100% of patients had no concerns, adverse outcomes or issues with noticeability of 
their donor site, with all patients being either somewhat or very satisfied with the final outcome and 
all donor sites showing complete healing. This is in comparison with SSG patients, of which three-
quarters found their donor site to be significantly more noticeable, half of whom experienced prob-
lems such as on-going pain, requiring analgesia and the donor taking longer than expected to heal, 
and only half being satisfied with the final outcome. PROM categories for noticeability, adverse 
problems and overall satisfaction were statistically significantly better in the CelluTome cohort.  
Cellutome patients have reduced discomfort, with previous studies also illustrating rapid healing of 
the donor site within a few days (11,12). 
There was no statistically significant difference between CelluTome and SSG patients when pa-
tients were asked about their opinion of their graft site. Furthermore, 80% of CelluTome patients 
were completely satisfied with the graft site outcome and the majority of patients showed good evi-
dence of healing at the graft site. These findings illustrate that patient perception of wound site 
healing with CelluTome grafts is satisfactory and similar to current standard therapy. The differ-
ence in patient perceptions of adverse outcomes of the graft site was approaching significance 
with SSG showing improved results. However this was related to issues with time to healing rather 
than complications and previous studies have shown excellent results with wound site healing 
when using CelluTome. In a small case series of patients with Pyoderma Gangrenosum the au-
thors found a significant reduction in wound size in all patients, with 60% of patients experiencing 
complete wound closure (12). Another study found a decrease in wound size in six out of seven 
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patients despite numerous patient comorbidities (11). However, larger studies are required to eval-
uate the effectiveness of CelluTome derived ESG in wound healing compared to SSG and a ran-
domised controlled trial comparing the two options in the future is essential. 
Our study also found that the average cost of using the CelluTome device was considerably less 
than both SSG and conservative dressing management per individual patient. An annual estimate 
based on twenty CelluTome patients per month shows a significant saving compared to traditional 
treatment options. The calculations are estimates and do not represent actual spending, however 
they provide an excellent overview of the potential financial benefits of this procedure. A particular 
benefit of CelluTome is its ease of use in an outpatient setting which is cost effective and more im-
portantly convenient for patients. Serena et al (2015) have also highlighted that the cost and sim-
plicity of the device make it an excellent option for resource-poor nations (11), as well as devel-
oped regions under contemporary austerity pressures. 
A limitation of the cost analysis is that the ultimate cost of each treatment event was based on an 
average of the patients in this study which takes into account the OPSC code plus each patients 
co-morbidities. Therefore ultimate revenue of each procedure will be variable as an HRG code will 
be calculated for each patient based on the treatments given and co-morbidities. It must also be 
highlighted that the costing in this article is based on UK coding procedures and therefore costing 
will vary in other healthcare systems based on different coding practices. 
The small sample size is the main limitation of this study, which makes statistically based conclu-
sions more difficult. However given this is a new experimental procedure there is not yet a large 
patient population from which to draw data and further studies are required to provide more evi-
dence. 
 
Conclusion 
Epidermal skin grafting using a CelluTome epidermal graft-harvesting device is associated with a 
significant improved patient perceived donor site outcomes when compared to SSG. This com-
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bined with the possible financial benefits and comparable graft site outcomes means ESG should 
be considered as a first line treatment option for both small chronic and acute wounds requiring 
skin coverage in the right patient.  
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Tables 
 CelluTome Patients (n=10) Split skin graft patients (n=10) 
Age: Average (range) 74 (50-93) 54.6 (19-94) 
Male:Female 3:7 6:4 
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Aetiology of wound   
Chronic traumatic wound 5 7 
Acute wound 3 3 
Venous ulcer 2 0 
Location of wound   
Leg 9 10 
Abdomen 1 0 
Average wound size (mean 
cm2) 
16.5 21 
 
Table 1: Demographics of patients included in the study 
 
 
 Noticeability Concerns Adverse Problems Overall Satisfaction 
Cellutome SSG Cellutome SSG Cellutome SSG Cellutome SSG 
Mean 1.0 3.3 1.0 1.8 1.0 2.2 1.2  2.7 
Standard 
Deviation 
0.00 1.64 0.00 1.23 0.00 1.23 0.42 1.64 
P value <0.01* 0.14 0.025* 0.03* 
 
Table 2: Summary of results of PROM for Donor Sites with P-Values from 1-Tailed Students T  
Test.  Statistically significant results are highlighted by * 
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 Noticeability Concerns Adverse Problems Overall Satisfaction 
Cellutome SSG Cellutome SSG Cellutome SSG Cellutome SSG 
Mean 3.6 3.9 2.4  2.2 2.4 1.3 2.4 1.8 
Standard 
Deviation 
1.43 1.10 1.43 1.62 1.65 0.48 0.97 0.63 
P value 0.3 0.47 0.12 0.096 
 
 
 
Table 3: Summary of results of PROM for Graft Sites with p-values from Mann-Whitney U test.  
 
 50% reduction 100% reduction Failed grafts Average time to 100% re-
duction (weeks) 
ESG 2 6 2 6 
SSG 6 4 0 9 
 
 
 
Table 4: Comparison of ESG and SSG graft site healing outcomes 
 
 
Patient Event OPSC Code Average Individu-
al Cost (£) 
Average income 
per event (£) 
Loss/profit per 
event 
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Inpatient SSG S35.2 1060 1032 -28 
CelluTome S36.8 349 668 319 
Initial dressing clinic ap-
pointment 
S57.4 91 137 46 
Followup dressing clinic 
appointment 
S57.5 84 79 -5 
 
 
 
Table 5: Summary of average cost and income per patient event 
 
Treatment 
Option 
Expenditure 
per patient 
(£) 
Loss/profit 
per patient 
(£) 
Overall cost 
per patient 
(£) 
Annual ex-
penditure 
for 120 pa-
tients (£) 
Annual 
loss/profit 
for 120 pa-
tients (£) 
Overall an-
nual cost for 
120 patients 
(£) 
SSG + dress-
ing clinic fol-
lowup 
1487 -2 1489 178440 -240 178680 
CelluTome + 
dressing clin-
ic followup 
776 345 431 93120 41400 51720 
Dressing 
management 
only 
1267 -24 1291 152040 -2880 154920 
 
 
 
Table 6: Summary of overall loss/profit per treatment option for individual patients and annually 
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Figure Legends 
 
Figure 1: Graph illustrating overall individual costs per treatment option 
 
 
 
 
Appendix 1 
1. How noticeable do you find your donor site? 
Very noticeable - 5 Somewhat noticeable - 4 Slightly noticeable - 3 No particular feeling - 2 Not noticeable - 1 
     
 
 
 
2. Are you concerned about your donor site appearance? 
I worry very much - 5 I worry somewhat - 4 I worry a little - 3 No particular feeling - 2 I do not worry - 1 
     
 
 
3. Did you suffer any problems with your donor site? 
Very problematic - 5 Somewhat problematic - 4 Slightly problematic - 3 No particular feeling - 2 Not problematic - 1 
     
 
 
4. Overall how would you rate the outcome of your donor site? 
Very unsatisfied - 
6 
Somewhat unsatisfied - 
5 
Slightly unsatisfied 
- 4 
Slightly satisfied - 3 Somewhat satis-
fied - 2 
Very satisfied - 1 
      
 
 
5. How noticeable do you find your graft site? 
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Very noticeable - 5 Somewhat noticeable - 4 Slightly noticeable - 3 No particular feeling - 2 Not noticeable - 1 
     
 
 
 
6. Are you concerned about your graft site appearance? 
I worry very much - 5 I worry somewhat - 4 I worry a little - 3 No particular feeling - 2 I do not worry - 1 
     
 
 
 
7. Did you suffer any problems with your graft site? 
Very problematic - 5 Somewhat problematic - 4 Slightly problematic - 3 No particular feeling - 2 Not problematic - 1 
     
 
 
 
8. Overall how would you rate the outcome of your graft site? 
Very unsatisfied - 
6 
Somewhat unsatisfied - 
5 
Slightly unsatisfied 
- 4 
Slightly satisfied - 3 Somewhat satis-
fied - 2 
Very satisfied - 1 
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